Life sciences companies face unique issues in accessing capital markets, including matters related to due diligence, public relations, regulatory and intellectual property. Goodwin offers a team of sophisticated life sciences lawyers who have expertise with these issues and extensive experience across the full breadth of equity and debt capital markets, advising issuers, sponsors, underwriters and investors in a variety of transactions to ensure deals close smoothly and in a timely way.
With over 150 lawyers focused on serving over 600 life sciences clients, our integrated, full service life sciences team offers deep transactional expertise drawing on firm resources spread across the globe. Since 2010, the firm has advised on more than 150 emerging company IPOs raising an excess of $25 billion. Over the years, Goodwin has been ranked among the top law firms for biotech IPOs issuer representation. In the past two years, Goodwin has advised twenty three biotechnology issuers on their IPOs totaling an aggregate of $4.1 billion.
2021
Company Name |
Company
|
Underwriters |
IPO Date |
Offer Price to the Public |
Aggregate Offering Raise |
Original Price Range |
Goodwin Participation,
|
| Design Therapeutics (NASDAQ: DSGN) |
Small-molecule therapies for genetic diseases | Goldman Sachs SVB Leerink Piper Sandler |
3/25/2021 S-1 |
$20 | $276 million | $18 – $20 | |
| Edgewise Therapeutics (NASDAQ: EWTX) |
Small molecule therapies for rare muscle disorders | J.P. Morgan Goldman Sachs SVB Leerink |
3/25/2021 S-1 |
$16 | $202.4 million | $14 – $16 | |
| Ikena Oncology (NASDAQ: IKNA) |
Novel cancer therapies | Jefferies Cowen & Co. Credit Suisse William Blair |
3/25/2021 S-1 |
$16 | $143.8 million | $15 – $17 | Issuer |
| LAVA Therapeutics (NASDAQ: LVTX) |
Novel bispecific antibodies for cancer | J.P. Morgan Jefferies SVB Leerink |
3/24/2021 F-1 |
$15 | $100.5 million | $14 – $16 | |
| Connect Biopharma (NASDAQ: CNTB) |
Therapies for T-cell driven inflammatory diseases | Jefferies SVB Leerink Piper Sandler China International Capital Corporation |
3/18/2021 F-1 |
$17 | $219.9 million | $15 – $17 | |
| Instil Bio (NASDAQ: TIL) |
Immune cell therapies for cancer | Morgan Stanley Jefferies Cowen & Co. |
3/18/2021 S-1 |
$20 | $368 million | $17 – $19 | |
| Finch Therapeutics (NASDAQ: FNCH) |
Microbiome therapeutics | BofA Securities Jefferies Evercore |
3/18/2021 S-1 |
$17 | $127.5 million | $15 – $17 | Underwriters |
| Prometheus Biosciences (NASDAQ: RXDX) |
Precision antibody therapies for inflammatory bowel disease | SVB Leerink Credit Suisse Stifel Nicolaus Guggenheim |
3/11/2021 S-1 |
$19 | $218.5 million | $16 – $18 | |
| Longboard Pharmaceuticals (NASDAQ: LBPH) |
Medicines for neurological diseases | Citigroup Evercore Guggenheim Cantor Fitzgerald |
3/11/2021 S-1 |
$16 | $80 million | $14 – $16 | |
| NexImmune (NASDAQ: NEXI) |
T cell focused immunotherapies for cancer | Barclays Cantor Fitzgerald Raymond James Allen & Company |
2/11/2021 S-1 |
$17 | $126.5 million | $15 – $17 | |
| Decibel Therapeutics (NASDAQ: DBTX) |
Gene therapy for hearing disorders | Citigroup SVB Leerink BMO Capital Markets Barclays Capital |
2/11/2021 S-1 |
$18 | $127 million | $16 – $18 | Underwriter |
| Adagene (NASDAQ: ADAG) |
Antibody-based cancer immunotherapies | Goldman Sachs (Asia) Morgan Stanley Jefferies China Renaissance Securities (Hong Kong) |
2/08/2021 F-1 |
$19 | $161 million | $17 – $19 | |
|
Vor Biopharma
|
Hematological malignancy therapies | Goldman Sachs Evercore Barclays Capital Stifel Nicolaus |
2/05/2021 S-1 |
$18 | $203.4 million | $16 – $18 | |
|
Angion Biomedica
|
Fibrotic disease therapies | Cowen & Co. Stifel Nicolaus H.C. Wainwright Oppenheimer |
2/04/2021 S-1 |
$16 | $92 million | $14 – $16 | |
|
Bolt Biotherapeutics
|
Tumor-targeted therapies | Morgan Stanley SVB Leerink Stifel Nicolaus Guggenheim |
2/04/2021 S-1 |
$20 | $264.5 million | $16 – $18 | |
|
Immunocore
|
T-Cell immunotherapies | Goldman Sachs J.P. Morgan Jefferies |
2/04/2021 F-1 |
$26 | $297.1 million | $23 – $25 | |
|
|
Therapies for rare diseases | Morgan Stanley BofA Securities Sunrise Securities Oppenheimer Kempen & Co |
2/04/2021 F-1 |
$20 | $190.2 million | $17 – $19 | |
|
Terns Pharmaceuticals
|
Therapies to treat liver diseases | J.P. Morgan Goldman Sachs Cowen & Co. |
2/04/2021 S-1 |
$17 | $146.6 million | $15 – $17 | |
|
Sensei Biotherapeutics
|
Immunotherapies to treat cancer | Citigroup Piper Sandler Berenberg Capital Markets Oppenheimer |
2/03/2021 S-1 |
$19 | $152.6 million | $16 – $18 | Underwriters |
|
Landos Biopharma
|
Therapeutics for autoimmune diseases | J.P. Morgan Jefferies SVB Leerink Raymond James |
2/03/2021 S-1 |
$16 | $100 million | $15 – $17 | |
|
Sana Biotechnology
|
Cell engineering and gene-based therapies | Morgan Stanley Goldman Sachs J.P. Morgan BofA Securities |
2/03/2021 S-1 |
$25 | $675.6 million | $20 – $23 | |
| Cullinan Management (NASDAQ: CGEM) |
Targeted & immuno-oncology therapies | Morgan Stanley SVB Leerink Evercore H.C. Wainwright |
1/07/2021 S-1 |
$21 | $287.4 million | $17 – $19 | Issuer |
| Gracell Biotechnologies (NASDAQ: GRCL) |
CAR-T cell therapies to treat cancer | Citigroup Jefferies Piper Sandler Wells Fargo |
1/07/2021 F-1 |
$19 | $209 million | $16 – $18 |
2020
Company Name |
Company
|
Underwriters |
IPO Date |
Offer Price to the Public |
Aggregate Offering Raise |
Original Price Range |
Goodwin Participation,
|
| BioAtla (NASDAQ: BCAB) |
Therapies for solid tumor cancer | J.P. Morgan Jefferies Credit Suisse |
12/15/2020 S-1 |
$18 | $217.4 million | $15 – $17 | |
| AbCellera Biologics (NASDAQ: ABCL) |
AI-powered drug discovery platform | Credit Suisse Sifel Nicolaus Berenberg Capital Markets SVB Leerink BMO Capital Markets |
12/10/2020 S-1 |
$20 | $555.5 million | $14-$17 | Issuer |
| 4D Molecular Therapeutics (NASDAQ: FDMT) |
Gene therapies to treat diseases | Goldman Sachs BofA Securities Evercore |
12/10/2020 S-1 |
$23 | $222 million | $20 – $22 | |
| Nanobiotix (NASDAQ: NBTX) |
Nanotech to help treat cancer | Jefferies Evercore UBS |
12/10/2020 F-1 |
$11.14 | $100.4 million | $14.69 | |
| Seer (NASDAQ: SEER) |
Protein profiling technologies | J.P. Morgan Morgan Stanley BofA Securities Cowen and Co. |
12/03/2020 S-1 |
$19 | $201.3 million | $16-$18 | |
| Sigilon Therapeutics (NASDAQ: SGTX) |
Therapies for chronic diseases | Morgan Stanley Jefferies Barclays Capital Canaccord Genuity |
12/03/2020 S-1 |
$18 | $144.9 million | $17 – $19 | |
| Silverback Therapeutics (NASDAQ: SBTX) | Tissue targeted therapeutics for cancer | Goldman Sachs SVB Leerink Stifel Nicolaus |
12/03/2020 S-1 |
$21 | $277.7 million | $17-$19 | |
| Kinnate Biopharma (NASDAQ: KNTE) |
Genomically defined cancer therapeutics | Goldman Sachs SVB Leerink Piper Sandler |
12/02/2020 S-1 |
$20 | $276 million | $16-$18 | |
| Maravai LifeSciences (NASDAQ: MRVI) | Products in support of biopharma R&D | Morgan Stanley Jefferies Goldman Sachs |
11/19/2020 S-1 |
$27 | $1.86 billion | $24 – $27 | |
| Olema Pharmaceuticals (NASDAQ: OLMA) | Therapies for women’s cancers | J.P. Morgan Jefferies Cowen & Co. Canaccord Genuity |
11/18/2020 S-1 |
$19 | $240.4 million | $16 – $18 | |
| Atea Pharmaceuticals (NASDAQ: AVIR) |
Antiviral therapeutics | J.P. Morgan Morgan Stanley Evercore William Blair |
10/29/2020 S-1 |
$24 | $345 million | $22 – $24 | |
| SQZ Biotechnologies (NYSE: SQZ) |
Cell therapies for cancer | BofA Securities Evercore Stifel Nicolaus BTIG |
10/29/2020 S-1 |
$16 | $81 million | $16 – $18 | Underwriter |
| Galecto (NASDAQ: GLTO) |
Therapeutics for fibrotic diseases | BofA Securities SVB Leerink Credit Suisse |
10/28/2020 S-1 |
$15 | $85 million | $14 – $16 | Issuer |
| Foghorn Therapeutics (NASDAQ: FHTX) |
Gene expression to battle cancer | Goldman Sachs Morgan Stanley Cowen & Co. |
10/22/2020 S-1 |
$16 | $120 million | $15-$17 | |
| Abcam (NASDAQ: ABCM) |
Medical reagents & diagnostics | Morgan Stanley BofA Securities SVB Leerink Lazard Freres William Blair |
10/21/2020 F-1 |
$17.50 | $180 million | $16.52 | |
| Opthea (NASDAQ: OPT) |
Therapies for retinal diseases | Citigroup SVB Leerink Oppenheimer Truist Securities |
10/16/2020 F-1 |
$13.50 | $128.2 million | $17.26 | Underwriter |
| Aligos Therapeutics (NASDAQ: ALGS) |
Therapeutics for viral and liver diseases | J.P. Morgan Jefferies Piper Sandler Cantor Fitzgerald |
10/15/2020 S-1 |
$15 | $150 million | $15-$16 | |
| Praxis Precision Medicines (NASDAQ: PRAX) |
Central nervous system therapies | Cowen & Co. Evercore Piper Sandler Wedbush Securities |
10/15/2020 S-1 |
$19 | $218.5 million | $16-$18 | Issuer |
| Codiak Biosciences (NASDAQ: CDAK) |
Therapeutics using exosome biology | Goldman Sachs Evercore William Blair Wedbush Securities |
10/13/2020 S-1 |
$15 | $82.5 million | $14-$16 | Issuer |
| Kronos Bio (NASDAQ: KRON) |
Cancer therapeutics | Goldman Sachs Jefferies Cowen & Co. Piper Sandler |
10/8/2020 S-1 |
$19 | $287.5 million | $16-$18 | |
| Shattuck Labs (NASDAQ: STTK) |
Immuno-oncology protein therapies | Citigroup Cowen & Co. Evercore Needham |
10/8/2020 S-1 |
$17 | $232.3 million | $14-$16 | |
| Spruce Biosciences (NASDAQ: SPRB) |
Endocrine disorder therapies | Cowen & Co. SVB Leerink Credit Suisse RBC Capital Markets |
10/8/2020 S-1 |
$15 | $103.5 million | $14-$16 | |
| Aziyo Biologics (NASDAQ: AZYO) |
Tissue regenerating medical products | Piper Sandler Cowen & Co. Cantor Fitzgerald Truist Securities |
10/7/2020 S-1 |
$17 | $50 million | $16-$18 | |
| C4 Therapeutics (NASDAQ: CCCC) |
Drugs to destroy target proteins | Jefferies Evercore BMO Capital Markets UBS |
10/1/2020 S-1 |
$19 | $209.76 million | $16-$18 | Issuer |
| Immunome (NASDAQ: IMNM) |
Antibody therapeutics | Ladenburg Thalmann Chardan Capital Markets |
10/1/2020 S-1 |
$12 | $44.85 million | $11-$13 | Underwriter |
| Oncorus (NASDAQ: ONCR) |
Viral immunotherapies for cancer | Jefferies Evercore Piper Sandler |
10/1/2020 S-1 |
$15 | $87 million | $14-$16 | |
| Orphazyme (NASDAQ: ORPH) |
Neurodegenerative disease therapies | BofA Securities Cowen & Co. Guggenheim Danske Markets |
9/28/2020 F-1 |
$11 | $50.17 million | $13.13 | |
| Graybug Vision (NASDAQ: GRAY) |
Medicines to treat ocular diseases | SVB Leerink Piper Sandler |
9/24/2020 S-1 |
$16 | $90 million | $15-$17 | |
| PMV Pharmaceuticals (NASDAQ: PMVP) | Tumor-agnostic cancer therapies | Goldman Sachs BofA Securities Cowen & Co. Evercore |
9/24/2020 S-1 |
$18 | $243.53 million | $16-$18 | |
| Prelude Therapeutics (NASDAQ: PRLD) | Small molecule cancer therapies | Morgan Stanley Goldman Sachs BofA Securities |
9/24/2020 S-1 |
$19 | $181.90 million | $17-$19 | |
| Taysha Gene Therapies (NASDAQ: TSHA) |
Therapies for monogenic diseases | Goldman Sachs Morgan Stanley Jefferies |
9/23/2020 S-1 |
$20 | $181 million | $18-$20 | Underwriter |
| Athira Pharma (NASDAQ: ATHA) |
Therapeutics for neurological diseases | Goldman Sachs Jefferies Stifel Nicolaus |
9/17/2020 S-1 |
$17 | $204 million | $15-$17 | |
| COMPASS Pathways (NASDAQ: CMPS) |
Psilocybin therapies for depression | Cowen & Co. Evercore Berenberg Capital Markets |
9/17/2020 F-1 |
$17 | $146.60 million | $14-$16 | Issuer |
| Dyne Therapeutics (NASDAQ: DYN) |
Therapies for genetic muscular diseases | J.P. Morgan Jefferies Piper Sandler Stifel Nicolaus |
9/16/2020 S-1 |
$19 | $268 million | $16-$18 | |
| Metacrine (NASDAQ: MTCR) |
Liver and gastrointestinal therapies | Jefferies Evercore RBC Capital Markets Canaccord Genuity |
9/15/2020 S-1 |
$13 | $85.02 million | $12-$14 | |
| Kymera Therapeutics (NASDAQ: KYMR) | Small molecule protein degraders | Morgan Stanley BofA Securities Cowen & Co. Guggenheim |
8/20/2020 S-1 |
$20 | $199.75 million | $16-$18 | Issuer |
| Harmony Biosciences (NASDAQ: HRMY) | Therapies for neurological disorders | Goldman Sachs Jefferies Piper Sandler |
8/18/2020 S-1 |
$24 | $147.62 million | $20-$23 | Underwriter |
| Inhibrx (NASDAQ: INBX) |
Protein therapies to treat cancer | Jefferies Evercore Credit Suisse |
8/18/2020 S-1 |
$17 | $136.85 million | $16-$18 | |
| CureVac (NASDAQ: CVAC) |
Messenger RNA-based therapies | BofA Securities Jefferies Credit Suisse |
8/13/2020 F-1 |
$16 | $245.33 million | $14-$16 | |
| Checkmate Pharmaceuticals (NASDAQ: CMPI) |
Therapeutics to treat cancer | BofA Securities Jefferies BMO Capital Markets |
8/06/2020 S-1 |
$15 | $75 million | $14-$16 | Issuer |
| Freeline Therapeutics (NASDAQ: FRLN) |
Gene therapies for monogenic diseases | J.P. Morgan Morgan Stanley Evercore |
8/06/2020 F-1 |
$18 | $158.82 million | $16-$18 | Underwriter |
| Acutus Medical (NASDAQ: AFIB) |
Cardiac arrhythmia treatments | J.P. Morgan BofA Securities William Blair |
8/05/2020 S-1 |
$18 | $182.64 million | $16-$18 | |
| Oak Street Health (NYSE: OSH) |
Healthcare for adults on Medicare | J.P. Morgan Goldman Sachs Morgan Stanley |
8/05/2020 S-1 |
$21 | $377.34 million | $15-$17 | |
| AlloVir (NASDAQ: ALVR) |
Allogenic T cell therapies | Morgan Stanley J.P. Morgan SVB Leerink Piper Sandler |
7/29/2020 S-1 |
$17 | $317.68 million | $16-$18 | Issuer |
| Annexon (NASDAQ: ANNX) |
Complement-mediated disorder therapies | J.P. Morgan BofA Securities Cowen & Co. |
7/23/2020 S-1 |
$17 | $288.36 million | $14-$16 | |
| Inozyme Pharma (NASDAQ: INZY) |
Treatments for abnormal mineralization | BofA Securities Cowen & Co. Piper Sandler |
7/23/2020 S-1 |
$16 | $128.8 million | $14-$16 | |
| iTeos Therapeutics (NASDAQ: ITOS) |
Immuno-oncology therapeutics | J.P. Morgan SVB Leerink Piper Sandler |
7/23/2020 S-1 |
$19 | $231.31 million | $16-$18 | Issuer |
| Nurix Therapeutics (NASDAQ: NRIX) |
Small molecule immuno-oncology agents | J.P. Morgan Piper Sandler Stifel Nicolaus |
7/23/2020 S-1 |
$19 | $240.35 million | $16-$18 | |
| ALX Oncology (NASDAQ: ALXO) |
Immuno-oncology therapies | Jefferies Credit Suisse Piper Sandler Cantor Fitzgerald |
7/16/2020 S-1 |
$19 | $185.7 million | $15-$17 | |
| Berkeley Lights (NASDAQ: BLI) |
Biotherapeutics and cell-based products | J.P. Morgan Morgan Stanley Cowen & Co. |
7/16/2020 S-1 |
$22 | $204.9 million | $16-$18 | |
| Pandion Therapeutics (NASDAQ: PAND) |
Therapeutics for autoimmune diseases | Goldman Sachs Morgan Stanley SVB Leerink BMO Capital Markets |
7/16/2020 S-1 |
$18 | $135 million | $16-$18 | Underwriter |
| Renalytix AI (NASDAQ: RNLX) |
AI-enabled in vitro diagnostics | J.P. Morgan Sitfel Nicolaus |
7/16/2020 F-1 |
$13.50 | $85.1 million | $14.22 | Underwriter |
| Relay Therapeutics (NASDAQ: RLAY) |
Small molecule therapeutics for cancer | J.P. Morgan Goldman Sachs Cowen & Co. Guggenheim |
7/15/2020 S-1 |
$20 | $460 million | $16-$18 | Issuer |
| Inventiva (NASDAQ: IVA) |
Non-alcoholic fatty liver treatments | Jefferies Stifel Nicolaus Guggenheim |
7/09/2020 F-1 |
$14.40 | $123.8 million | $13.68 | |
| NKarta (NASDAQ: NKTX) |
Natural killer cell cancer therapies | Cowen & Co. Evercore Stifel Nicolaus Mizuho |
7/09/2020 S-1 |
$18 | $289.8 million | $14-1$16 | |
| Poseida Therapeutics (NASDAQ: PSTX) |
Cell and gene therapeutics | BofA Securities Piper Sandler William Blair |
7/09/2020 S-1 |
$16 | $257.6 million | $14-$16 | |
| Akouos, Inc. NASDAQ (AKUS) |
Gene therapies for hearing loss | BofA Securities Cowen & Co. Piper Sandler |
06/25/2020 S-1 |
$17.00 | $244.37 million |
$14.00 – $16.00 |
|
| Forma Therapeutics Holdings, Inc. NASDAQ (FMTX) |
Cancer & hematologic disease therapies | Jefferies SVB Leerink Credit Suisse |
06/25/2020 S-1 |
$20.00 | $319.29 million |
$16.00 – $18.00 |
Issuer |
| PolyPid Ltd. NASDAQ (PYPD) |
Therapies to improve surgical outcomes | Barclays Capital BMO Capital Markets Raymond James |
06/25/2020 F-1 |
$16.00 | $69.00 million |
$15.00 – $17.00 |
|
| Progenity, Inc. NASDAQ (PROG) |
Molecular testing products | Piper Sandler Wells Fargo Securities |
06/19/2020 S-1 |
$15.00 | $115.00 million |
$14.00 – $16.00 |
|
| Repare Therapeutics Inc. NASDAQ (RPTX) |
Genomic-focused cancer therapies | Morgan Stanley Goldman Sachs Cowen & Co. Piper Sandler |
06/18/2020 S-1 |
$20.00 | $253.00 million |
$16.00 – $18.00 |
Underwriter |
| Genetron Holdings Limited NASDAQ (GTH) |
Cancer molecular profiling technologies | Credit Suisse China International Capital Corporation |
06/18/2020 F-1 |
$16.00 | $294.4 million |
$11.50 – $13.50 |
|
| Royalty Pharma plc NASDAQ (RPRX) |
Biopharmaceutical royalties acquisition | J.P. Morgan Morgan Stanley BofA Securities Goldman Sachs Citigroup UBS Securities |
06/15/2020 S-1 |
$28.00 | $2.5 billion |
$25.00 – $28.00 |
Underwriter |
| Avidity Biosciences, Inc. NASDAQ (RNA) |
Therapeutics to treat serious diseases | Cowen & Co. SVB Leerink Credit Suisse Wells Fargo Securities |
06/11/2020 S-1 |
$18.00 | $298.08 million |
$14.00 – $16.00 |
|
| Burning Rock Biotech Limited NASDAQ (BNR) |
Cancer therapy selection services | Morgan Stanley BofA Securities Cowen & Co. |
06/11/2020 F-1 |
$16.50 | $256.16 million |
$13.50 – $15.50 |
|
| Generation Bio Co. NASDAQ (GBIO) |
Non-viral gene therapies | J.P. Morgan Jefferies Cowen & Co. Wedbush Securities |
06/11/2020 S-1 |
$19.00 | $229.99 million |
$16.00 – $18.00 |
|
| Vaxcyte, Inc. NASDAQ (PCVX) |
Pneumococcal conjugate vaccines | BofA Securities Jefferies Evercore |
06/11/2020 S-1 |
$16.00 | $287.50 million |
$14.00 – $16.00 |
|
| Fusion Pharmaceuticals Inc. NASDAQ (FUSN) |
Radiopharmaceuticals to treat cancers | Morgan Stanley Jefferies Cowen & Co. |
06/05/2020 S-1 |
$17.00 | $244.37 million |
$14.00 – $16.00 |
Issuer |
| Legend Biotech Corporation NASDAQ (LEGN) |
Cell therapies to treat cancer | Morgan Stanley J.P. Morgan Jefferies |
06/05/2020 F-1 |
$23.00 | $487.34 million |
$18.00 – $20.00 |
|
| Applied Molecular Transport Inc. NASDAQ (AMTI) |
Oral biologic products to treat disease | BofA Securities Jefferies SVB Leerink |
06/04/2020 S-1 |
$14.00 | $177.10 million | $12.00 – $14.00 | |
| Calliditas Therapeutics NASDAQ (CALT) |
Treatment for autoimmune renal disease | Citigroup Jefferies Stifel, Nicolaus |
06/04/2020 F-1 |
$19.50 | $90.00 million |
$19.77 | Issuer |
| Pliant Therapeutics, Inc. NASDAQ (PLRX) |
Fibrosis therapeutics | Citigroup Cowen & Co. Piper Sandler |
06/02/2020 S-1 |
$16.00 | $165.60 million |
$14.00- $16.00 |
Issuer |
| Inari Medical, Inc. NASDAQ (NARI) |
Thrombectomy devices | BofA Securities Morgan Stanley |
05/21/2020 S-1 |
$19.00 | $179.22 million |
$14.00 – $16.00 |
|
| ADC Therapeutics SA NASDAQ (ADCT) |
Blood cancer therapies | Morgan Stanley BofA Securities Cowen & Co. |
05/14/2020 F-1 |
$19.00 | $267.56 million |
$16.00 – $18.00 |
|
| Ayala Pharmaceuticals, Inc. NASDAQ (AYLA) |
Small molecule therapies for cancer | Citigroup Jefferies |
05/07/2020 S-1 |
$15.00 | $63.25 million |
$14.00- $16.00 |
|
| Lyra Therapeutics, Inc. NASDAQ (LYRA) |
Localized ear, nose & throat treatments | BofA Securities Jefferies William Blair |
04/30/2020 S-1 |
$16.00 | $64.40 million |
$14.00 – $16.00 |
|
| ORIC Pharmaceuticals, Inc. NASDAQ (ORIC) |
Therapies to treat cancer | J.P. Morgan Citigroup Jefferies Guggenheim |
04/23/2020 S-1 |
$16.00 | $138.00 million |
$14.00- $16.00 |
|
| Keros Therapeutics, Inc. NASDAQ (KROS) |
Treatment for hematological disorders | Jefferies SVB Leerink Piper Sandler |
04/07/2020 S-1 |
$16.00 | $110.40 million |
$14.00- $16.00 |
|
| Zentalis Pharmaceuticals, Inc. NASDAQ (ZNTL) |
Small molecule cancer therapies | Morgan Stanley Jefferies SVB Leerink Guggenheim |
04/02/2020 S-1 |
$18.00 | $190.02 million |
$16.00 – $18.00 |
|
| IMARA Inc. NASDAQ (IMRA) |
Therapies for hemoglobinopathies | Morgan Stanley Citigroup SVB Leerink |
03/11/2020 S-1 |
$16.00 | $86.48 million |
$16.00 – $18.00 |
|
| Passage Bio, Inc. NASDAQ (PASG) |
CNS disorder therapies | J.P. Morgan Goldman Sachs Cowen & Co. |
02/27/2020 S-1 |
$18.00 | $248.4 million |
$16.00 – $18.00 |
|
| Revolution Medicines, Inc. NASDAQ (RVMD) |
Protein therapies to treat cancer | J.P. Morgan Cowen & Co. SVB Leerink Guggenheim |
02/12/2020 S-1 |
$17.00 | $273.7 million |
$14.00- $16.00 |
|
| Beam Therapeutics, Inc. NASDAQ (BEAM) |
Gene Editing | J.P. Morgan Jefferies Barclays Capital |
02/05/2020 S-1 |
$17.00 | $207 million |
$15.00 – $17.00 |
|
| PPD, Inc. NASDAQ (PPD) |
Drug development & laboratory svcs | Barclays Capital J.P. Morgan Morgan Stanley Goldman Sachs |
02/05/2020 S-1 |
$27.00 | $1.80 billion |
$24.00 – $27.00 |
|
| 1Life Healthcare NASDAQ (ONEM) |
Digital healthcare platform | J.P. Morgan Morgan Stanley |
01/30/2020 S-1 |
$14.00 | $281.00 million |
$14.00 – $16.00 |
|
| Arcutis Biotherapeutics, Inc. NASDAQ (ARQT) |
Treatments for dermatological diseases | Goldman Sachs Cowen & Co. Guggenheim |
01/30/2020 S-1 |
$17.00 | $183.28 million |
$15.00 – $17.00 |
|
| Black Diamond Therapeutics NASDAQ (BDTX) |
Small molecule tumor-agnostic therapies | J.P. Morgan Jefferies Cowen & Co. |
01/29/2020 S-1 |
$19.00 | $231.3 million |
$16.00 – $18.00 |
Issuer |
| I-Mab NASDAQ (IMAB) |
Drugs for cancers & autoimmune diseases | Jefferies China International Capital Corporation |
01/16/2020 F-1 |
$14.00 | $119.25 million |
$12.00 – $15.00 |